Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature

Găman, Mihnea‐Alexandru; Cozma, Matei-Alexandru; Manan, Muhammad Romail; Srichawla, Bahadar S; Dhali, Arkadeep; Ali, Sajjad; Nahian, Ahmed; Elton, Andrew C.; Kutikuppala, LV Simhachalam; Suteja, Richard Christian; Diebel, Sebastian; Găman, Amelia Maria; Diaconu, Camelia Cristina

doi:10.5306/wjco.v14.i3.99

Cited by 9 publications

(5 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subjects suffering from MPNs exhibit a high burden of cardiovascular risk factors (CVRFs), thrombotic events often being the cause of death in this patient population[ 17 - 19 ]. In a recent publication by Seguro et al [ 20 ], the authors conducted a retrospective analysis of hemorrhagic and thrombotic events in a cohort of 334 Brazilian patients with Philadelphia-negative chronic MPNs.…”

Section: Brief Overview Of Cardiovascular Risk Factors In Mpnsmentioning

confidence: 99%

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Găman,

Srichawla,

Chen

et al. 2024

World J Clin Oncol

Self Cite

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.

show abstract

Section: Brief Overview Of Cardiovascular Risk Factors In Mpnsmentioning

confidence: 99%

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Găman,

Srichawla,

Chen

et al. 2024

World J Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…This definition excludes all the forms of hepatic outflow obstruction caused by cardiac failure disease, constrictive pericarditis, and sinusoidal obstruction syndrome (SOS) [ 3 ]. In the primary form of BCS obstruction results from a pathologic process involving the veins as thrombosis or phlebitis; meanwhile, secondary BCS is caused by the extrinsic compression or invasion of the hepatic venous outflow by a mass located outside the veins (benign or malign tumor, abscesses, lymphadenopathy, parasitic, or non-parasitic cyst) [ 4 ]. Clinical presentation of BCS ranges from asymptomatic cases to fulminant liver failure depending on the degree and the rapidity of hepatic vein obstruction.…”

Section: Budd Chiari Syndromementioning

confidence: 99%

Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis

Giuli

Pallozzi

Venturini

et al. 2023

IJMS

View full text Add to dashboard Cite

Vascular liver disorders (VLDs) comprise a wide spectrum of clinical-pathological entities that primarily affect the hepatic vascular system of both cirrhotic and non-cirrhotic patients. VLDs more frequently involve the portal and the hepatic veins, as well as liver sinusoids, resulting in an imbalance of liver homeostasis with serious consequences, such as the development of portal hypertension and liver fibrosis. Surprisingly, many VLDs are characterized by a prothrombotic phenotype. The molecular mechanisms that cause thrombosis in VLD are only partially explained by the alteration in the Virchow’s triad (hypercoagulability, blood stasis, and endothelial damage) and nowadays their pathogenesis is incompletely described and understood. Studies about this topic have been hampered by the low incidence of VLDs in the general population and by the absence of suitable animal models. Recently, the role of coagulation imbalance in liver disease has been postulated as one of the main mechanisms linked to fibrogenesis, so a novel interest in vascular alterations of the liver has been renewed. This review provides a detailed analysis of the current knowledge of molecular mechanisms of VLD. We also focus on the promising role of anticoagulation as a strategy to prevent liver complications and to improve the outcome of these patients.

show abstract

“…Gender disparities persist in the study of BCS, despite the condition's association with risk factors, such as oral contraceptive use and pregnancy, that predominantly affect women. Representation of females in BCS research, clinical cases, and literature remains varied, highlighting the need for further investigation into these disparities [ 3 , 4 , 5 ]. Furthermore, the number of female gastroenterologists and fellows is significantly lower than in other specialties for the past decade [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Study on the Analysis of Gender Trends Among the First Authors of Publications on Budd-Chiari Syndrome

Samuel B,

Parag Chitnavis,

Yadavalli

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Budd-Chiari syndrome (BCS) is primarily a disease of hepatic vein blockage, which involves a backflow of blood to the liver. Although there have been many causes linked to this disease, most commonly, it occurs due to hypercoagulable states and blood disorders. In recent times, there has been a fast spread of knowledge regarding early diagnosis and various treatment modalities, which has enabled the prevention of mortality in most cases. This has primarily spread through research articles published in various journals. Thus, the article aims to compare the gender trend ratios to identify the associated discrepancies in terms of male and female author contributions who have been the primary authors for articles pertaining to this disease. Methodology: A PubMed database between the years 2013 and 2022 was used for the bibliometric analysis. The gender of the primary author was analyzed by NamSor, an application programming interface (API). The statistical analysis was conducted using R software, the ARIMA model, and graphs were prepared using Datawrapper. Results: Out of 667 articles extracted, the analysis showed that there were 455 (68.2%) first male authors and 212 (31.8%) first female authors. We also formulated various other results, which depicted a higher female-to-male author ratio including various journals and different countries. Although there has been an increasing trend of male authors as compared to female authors, this study found that male authorship for research on this disease is still higher. Conclusions: This study depicts that there is a necessity to draw attention to the inequitable systems favoring men over women for publications. The predictive analysis conducted also helps to foresee the trend in the next few years and explains the necessity of addressing the disparities among both genders in healthcare systems.

show abstract

Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature

Cited by 9 publications

References 130 publications

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis

Study on the Analysis of Gender Trends Among the First Authors of Publications on Budd-Chiari Syndrome

Contact Info

Product

Resources

About